These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

930 related articles for article (PubMed ID: 27155969)

  • 61. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups.
    Gadji M; Adebayo Awe J; Rodrigues P; Kumar R; Houston DS; Klewes L; Dièye TN; Rego EM; Passetto RF; de Oliveira FM; Mai S
    Clin Cancer Res; 2012 Jun; 18(12):3293-304. PubMed ID: 22539801
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mesenchymal stromal cells of myelodysplastic syndrome and acute myeloid leukemia patients have distinct genetic abnormalities compared with leukemic blasts.
    Blau O; Baldus CD; Hofmann WK; Thiel G; Nolte F; Burmeister T; Türkmen S; Benlasfer O; Schümann E; Sindram A; Molkentin M; Mundlos S; Keilholz U; Thiel E; Blau IW
    Blood; 2011 Nov; 118(20):5583-92. PubMed ID: 21948175
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Multiplex imaging reveals spatially resolved DNA-damage response neighborhoods in TP53-mutated myelodysplastic neoplasms.
    Yeung T; Zhang Y; Kennedy B; Walsh C; Love T; Xia D; Bhattacharya A; Krishnan RG; Head D; Burack R
    J Pathol; 2024 Jul; 263(3):386-395. PubMed ID: 38801208
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies.
    Orazi A; Cattoretti G; Heerema NA; Sozzi G; John K; Neiman RS
    Mod Pathol; 1993 Sep; 6(5):521-5. PubMed ID: 8248107
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preferential occurrence of spliceosome mutations in acute myeloid leukemia with preceding myelodysplastic syndrome and/or myelodysplasia morphology.
    Cho YU; Jang S; Seo EJ; Park CJ; Chi HS; Kim DY; Lee JH; Lee JH; Lee KH; Koh KN; Im HJ; Seo JJ; Park SH; Park YM; Lee JK
    Leuk Lymphoma; 2015; 56(8):2301-8. PubMed ID: 25487075
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Expression and effect of neuropilin-1 in acute myeloid leukemic cells].
    Lu L; Zhang L; Xiao ZJ; Lu SH; Wang GS; Yang RC; Han ZC
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1150-5. PubMed ID: 18088455
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pirin downregulation is a feature of AML and leads to impairment of terminal myeloid differentiation.
    Licciulli S; Cambiaghi V; Scafetta G; Gruszka AM; Alcalay M
    Leukemia; 2010 Feb; 24(2):429-37. PubMed ID: 20010624
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.
    Mann KP; DeCastro CM; Liu J; Moore JO; Bigner SH; Traweek ST
    Am J Clin Pathol; 1997 Jun; 107(6):653-60. PubMed ID: 9169661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Niparuck P; Police P; Noikongdee P; Siriputtanapong K; Limsuwanachot N; Rerkamnuaychoke B; Chuncharunee S; Siriboonpiputtana T
    Diagn Pathol; 2021 Oct; 16(1):100. PubMed ID: 34717674
    [TBL] [Abstract][Full Text] [Related]  

  • 73. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.
    Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R
    Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Increase of DNA damage and alteration of the DNA damage response in myelodysplastic syndromes and acute myeloid leukemias.
    Popp HD; Naumann N; Brendel S; Henzler T; Weiss C; Hofmann WK; Fabarius A
    Leuk Res; 2017 Jun; 57():112-118. PubMed ID: 28359030
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
    Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
    Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Myelodysplastic syndrome with t(6;9)(p22;q34.1)/DEK-NUP214 better classified as acute myeloid leukemia? A multicenter study of 107 cases.
    Fang H; Yabe M; Zhang X; Kim Y; Wu X; Wei P; Chi S; Zheng L; Garcia-Manero G; Shao L; Yuan J; Shen Y; Zheng G; Tang G; Wang W; Loghavi S; Shen Q; Yuan Y; He R; Chen D; Medeiros LJ; Hu S
    Mod Pathol; 2021 Jun; 34(6):1143-1152. PubMed ID: 33558656
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Molecular pathways in myelodysplastic syndromes and acute myeloid leukemia: relationships and distinctions-a review.
    Bernasconi P
    Br J Haematol; 2008 Sep; 142(5):695-708. PubMed ID: 18540941
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.
    Dicker F; Haferlach C; Sundermann J; Wendland N; Weiss T; Kern W; Haferlach T; Schnittger S
    Leukemia; 2010 Aug; 24(8):1528-32. PubMed ID: 20520634
    [No Abstract]   [Full Text] [Related]  

  • 80. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
    Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.